Drug Trial Radar · NCT04030598
A Study to Assess the Clinical Efficacy of Donidalorsen (Also Known as IONIS-PKK-LRx and ISIS 721744) in Participants With Hereditary Angioedema
Last checked: Nov 20, 2026Latest source record: Apr 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
23
Actual
Start
Jan 7, 2020
Primary completion
Jan 4, 2021
Study completion Mar 1, 2021
Sponsor
- Lead sponsor
- Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
- Sponsor type
- Industry
- First posted
- Jul 24, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to evaluate the clinical efficacy, safety, and tolerability of donidalorsen in participants with hereditary angioedema (HAE) type 1 (HAE-1), HAE type 2 (HAE-2), or HAE with normal C1-inhibitor (C1-INH) and to evaluate the effect of donidalorsen on plasma prekallikrein (PKK) and other relevant biomarkers.
Conditions
- Hereditary Angioedema
Interventions
DonidalorsenDrug
Donidalorsen administered SC
PlaceboDrug
Placebo matching solution administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time-normalized Number of HAE Attacks (Per Month) From Week 1 to Week 17Time frame: Week 1 to Week 17
Locations
8 sites in 2 countries. Site status is shown where the registry gives one.
Medical Research of Arizona
Scottsdale, Arizona
University of California San Diego (UCSD)
San Diego, California
AIRE Medical of Los Angeles
Santa Monica, California
Midwest Immunology Clinical
Plymouth, Minnesota
Bernstein Clinical Research Center, LLC
Cincinnati, Ohio
Penn State Hershey Medical Center
Hershey, Pennsylvania
AARA Research Center
Dallas, Texas
Amsterdam UMC, loc. AMC
Amsterdam, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.